Temperature guided high and very high-power short duration ablation for atrial fibrillation treatment - The peQasus multicentre study
Temperature-controlled high-power short-duration (HPSD) radiofrequency catheter ablation for pulmonary vein isolation (PVI) utilizing a novel ablation catheter (QDOT Micro) with real-time assessment of catheter tip temperature aims for safer, more effective and faster procedures. The peQasus study i...
Gespeichert in:
| Veröffentlicht in: | Europace (London, England) England), 2024-11 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Europace (London, England) |
| container_volume | |
| creator | Heeger, Christian-Hendrik Almorad, Alexandre Scherr, Daniel Szegedi, Nándor Baran, Jakub Duytschaever, Mattias Gupta, Dhiraj Linz, Dominik Lyan, Evgeny Leventopoulos, Georgios Popescu, Sorin Stefan Rauber, Martin Kollias, Georgios Niedzwiedz, Michał Sarkozy, Andrea Badoz, Marc Sohns, Christian Ginks, Matthew R Pürerfellner, Helmut Tilz, Roland R |
| description | Temperature-controlled high-power short-duration (HPSD) radiofrequency catheter ablation for pulmonary vein isolation (PVI) utilizing a novel ablation catheter (QDOT Micro) with real-time assessment of catheter tip temperature aims for safer, more effective and faster procedures.
The peQasus study is a large European multicenter study set up to assess safety, acute efficacy and outcomes of temperature-controlled HPSD based PVI. The primary endpoints were safety, efficacy and 12-months freedom from atrial tachyarrhythmias. Additionally, two strategies namely very HPSD (90W for 4 seconds) only and a hybrid approach (HPSD with maximum of 50W and vHPSD) were compared.
A total of 1,023 AF patients in 15 centers from 9 European countries received PVI with the QDOT. Complete PVI was successfully achieved in all patients. In 699/1023 (68.3%) the vHPSD only approach (vHPSD group) and in 324/(31.7%) patients the hybrid approach (hybrid group) was utilized. The mean procedure duration was 98.4±37.4 min (vHPSD: 88.2±34.9min, hybrid: 117.4±32.7min, p |
| doi_str_mv | 10.1093/europace/euae284 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3125484702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3125484702</sourcerecordid><originalsourceid>FETCH-LOGICAL-c972-61264cf9a94e369a441d6936cf4e6fa6557fd6f02e235e13403f55570ed315de3</originalsourceid><addsrcrecordid>eNo9UMtOwzAQtBCIQuHOCfnIJeBnUh9RxUuqhJB6j9x43RolTfAD1A_gvzE05bSzo5nZ1SB0RcktJYrfQfL9oBvIQAObiSN0RiVnBSOKHWdMlCokZWqCzkN4J4RUTMlTNOFKEiErdoa-l9AN4HVMHvA6OQMGb9x6g_XW4E_wu7-tGPov8Dhseh-xSVnu-i3Wq3YPbO-xjt7pFlu38q4d-ehBxw62ERd4uQE8wJsOKeAutdE1mc83Q0xmd4FOrG4DXI5zipaPD8v5c7F4fXqZ3y-KRlWsKCkrRWOVVgJ4qbQQ1JSKl40VUFpdSllZU1rCgHEJlAvCrcwkAcOpNMCn6GYfO_j-I0GIdedCA_ndLfQp1JwyKWaiIixLyV7a-D4ED7YevOu039WU1L_d14fu67H7bLke09OqA_NvOJTNfwCWpIWx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3125484702</pqid></control><display><type>article</type><title>Temperature guided high and very high-power short duration ablation for atrial fibrillation treatment - The peQasus multicentre study</title><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Heeger, Christian-Hendrik ; Almorad, Alexandre ; Scherr, Daniel ; Szegedi, Nándor ; Baran, Jakub ; Duytschaever, Mattias ; Gupta, Dhiraj ; Linz, Dominik ; Lyan, Evgeny ; Leventopoulos, Georgios ; Popescu, Sorin Stefan ; Rauber, Martin ; Kollias, Georgios ; Niedzwiedz, Michał ; Sarkozy, Andrea ; Badoz, Marc ; Sohns, Christian ; Ginks, Matthew R ; Pürerfellner, Helmut ; Tilz, Roland R</creator><creatorcontrib>Heeger, Christian-Hendrik ; Almorad, Alexandre ; Scherr, Daniel ; Szegedi, Nándor ; Baran, Jakub ; Duytschaever, Mattias ; Gupta, Dhiraj ; Linz, Dominik ; Lyan, Evgeny ; Leventopoulos, Georgios ; Popescu, Sorin Stefan ; Rauber, Martin ; Kollias, Georgios ; Niedzwiedz, Michał ; Sarkozy, Andrea ; Badoz, Marc ; Sohns, Christian ; Ginks, Matthew R ; Pürerfellner, Helmut ; Tilz, Roland R</creatorcontrib><description>Temperature-controlled high-power short-duration (HPSD) radiofrequency catheter ablation for pulmonary vein isolation (PVI) utilizing a novel ablation catheter (QDOT Micro) with real-time assessment of catheter tip temperature aims for safer, more effective and faster procedures.
The peQasus study is a large European multicenter study set up to assess safety, acute efficacy and outcomes of temperature-controlled HPSD based PVI. The primary endpoints were safety, efficacy and 12-months freedom from atrial tachyarrhythmias. Additionally, two strategies namely very HPSD (90W for 4 seconds) only and a hybrid approach (HPSD with maximum of 50W and vHPSD) were compared.
A total of 1,023 AF patients in 15 centers from 9 European countries received PVI with the QDOT. Complete PVI was successfully achieved in all patients. In 699/1023 (68.3%) the vHPSD only approach (vHPSD group) and in 324/(31.7%) patients the hybrid approach (hybrid group) was utilized. The mean procedure duration was 98.4±37.4 min (vHPSD: 88.2±34.9min, hybrid: 117.4±32.7min, p<0.001). The first pass isolation rate of all PVs was 64% (vHPSD: 62.6%, hybrid: 67.1%, p=0.187). Severe adverse events were observed in 1.7% (vHPSD: 1.6%, hybrid: 1.9%, p=0.746). 12-month arrhythmia-recurrence free survival was 77.1% (vHPSD: 76.8%, hybrid: 77.8%, p=0.241).
In this large multicentre study temperature-controlled HPSD and vHPSD ablation via a novel ablation catheter provides safe and effective PVI with a relatively short procedure duration. Despite a shorter procedure time no differences in terms of safety and freedom from arrhythmia-recurrence were found irrespective of utilizing vHPSD or the hybrid approach.</description><identifier>ISSN: 1099-5129</identifier><identifier>ISSN: 1532-2092</identifier><identifier>EISSN: 1532-2092</identifier><identifier>DOI: 10.1093/europace/euae284</identifier><identifier>PMID: 39504572</identifier><language>eng</language><publisher>England</publisher><ispartof>Europace (London, England), 2024-11</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-3490-090X ; 0000-0001-5868-5493 ; 0000-0002-9014-8097 ; 0000-0001-5670-745X ; 0000-0001-8451-0013 ; 0000-0001-9696-9227 ; 0000-0002-9743-1661 ; 0000-0002-8965-8495 ; 0000-0002-5469-8833 ; 0000-0002-4704-4532 ; 0000-0001-5954-2451 ; 0000-0001-6327-0487 ; 0000-0003-4893-0824 ; 0000-0002-4199-4019 ; 0000-0002-0122-7130 ; 0000-0003-3049-5182 ; 0000-0002-3982-5101 ; 0000-0001-8769-9157 ; 0000-0003-0490-5862 ; 0009-0009-5354-9949</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39504572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Heeger, Christian-Hendrik</creatorcontrib><creatorcontrib>Almorad, Alexandre</creatorcontrib><creatorcontrib>Scherr, Daniel</creatorcontrib><creatorcontrib>Szegedi, Nándor</creatorcontrib><creatorcontrib>Baran, Jakub</creatorcontrib><creatorcontrib>Duytschaever, Mattias</creatorcontrib><creatorcontrib>Gupta, Dhiraj</creatorcontrib><creatorcontrib>Linz, Dominik</creatorcontrib><creatorcontrib>Lyan, Evgeny</creatorcontrib><creatorcontrib>Leventopoulos, Georgios</creatorcontrib><creatorcontrib>Popescu, Sorin Stefan</creatorcontrib><creatorcontrib>Rauber, Martin</creatorcontrib><creatorcontrib>Kollias, Georgios</creatorcontrib><creatorcontrib>Niedzwiedz, Michał</creatorcontrib><creatorcontrib>Sarkozy, Andrea</creatorcontrib><creatorcontrib>Badoz, Marc</creatorcontrib><creatorcontrib>Sohns, Christian</creatorcontrib><creatorcontrib>Ginks, Matthew R</creatorcontrib><creatorcontrib>Pürerfellner, Helmut</creatorcontrib><creatorcontrib>Tilz, Roland R</creatorcontrib><title>Temperature guided high and very high-power short duration ablation for atrial fibrillation treatment - The peQasus multicentre study</title><title>Europace (London, England)</title><addtitle>Europace</addtitle><description>Temperature-controlled high-power short-duration (HPSD) radiofrequency catheter ablation for pulmonary vein isolation (PVI) utilizing a novel ablation catheter (QDOT Micro) with real-time assessment of catheter tip temperature aims for safer, more effective and faster procedures.
The peQasus study is a large European multicenter study set up to assess safety, acute efficacy and outcomes of temperature-controlled HPSD based PVI. The primary endpoints were safety, efficacy and 12-months freedom from atrial tachyarrhythmias. Additionally, two strategies namely very HPSD (90W for 4 seconds) only and a hybrid approach (HPSD with maximum of 50W and vHPSD) were compared.
A total of 1,023 AF patients in 15 centers from 9 European countries received PVI with the QDOT. Complete PVI was successfully achieved in all patients. In 699/1023 (68.3%) the vHPSD only approach (vHPSD group) and in 324/(31.7%) patients the hybrid approach (hybrid group) was utilized. The mean procedure duration was 98.4±37.4 min (vHPSD: 88.2±34.9min, hybrid: 117.4±32.7min, p<0.001). The first pass isolation rate of all PVs was 64% (vHPSD: 62.6%, hybrid: 67.1%, p=0.187). Severe adverse events were observed in 1.7% (vHPSD: 1.6%, hybrid: 1.9%, p=0.746). 12-month arrhythmia-recurrence free survival was 77.1% (vHPSD: 76.8%, hybrid: 77.8%, p=0.241).
In this large multicentre study temperature-controlled HPSD and vHPSD ablation via a novel ablation catheter provides safe and effective PVI with a relatively short procedure duration. Despite a shorter procedure time no differences in terms of safety and freedom from arrhythmia-recurrence were found irrespective of utilizing vHPSD or the hybrid approach.</description><issn>1099-5129</issn><issn>1532-2092</issn><issn>1532-2092</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9UMtOwzAQtBCIQuHOCfnIJeBnUh9RxUuqhJB6j9x43RolTfAD1A_gvzE05bSzo5nZ1SB0RcktJYrfQfL9oBvIQAObiSN0RiVnBSOKHWdMlCokZWqCzkN4J4RUTMlTNOFKEiErdoa-l9AN4HVMHvA6OQMGb9x6g_XW4E_wu7-tGPov8Dhseh-xSVnu-i3Wq3YPbO-xjt7pFlu38q4d-ehBxw62ERd4uQE8wJsOKeAutdE1mc83Q0xmd4FOrG4DXI5zipaPD8v5c7F4fXqZ3y-KRlWsKCkrRWOVVgJ4qbQQ1JSKl40VUFpdSllZU1rCgHEJlAvCrcwkAcOpNMCn6GYfO_j-I0GIdedCA_ndLfQp1JwyKWaiIixLyV7a-D4ED7YevOu039WU1L_d14fu67H7bLke09OqA_NvOJTNfwCWpIWx</recordid><startdate>20241107</startdate><enddate>20241107</enddate><creator>Heeger, Christian-Hendrik</creator><creator>Almorad, Alexandre</creator><creator>Scherr, Daniel</creator><creator>Szegedi, Nándor</creator><creator>Baran, Jakub</creator><creator>Duytschaever, Mattias</creator><creator>Gupta, Dhiraj</creator><creator>Linz, Dominik</creator><creator>Lyan, Evgeny</creator><creator>Leventopoulos, Georgios</creator><creator>Popescu, Sorin Stefan</creator><creator>Rauber, Martin</creator><creator>Kollias, Georgios</creator><creator>Niedzwiedz, Michał</creator><creator>Sarkozy, Andrea</creator><creator>Badoz, Marc</creator><creator>Sohns, Christian</creator><creator>Ginks, Matthew R</creator><creator>Pürerfellner, Helmut</creator><creator>Tilz, Roland R</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3490-090X</orcidid><orcidid>https://orcid.org/0000-0001-5868-5493</orcidid><orcidid>https://orcid.org/0000-0002-9014-8097</orcidid><orcidid>https://orcid.org/0000-0001-5670-745X</orcidid><orcidid>https://orcid.org/0000-0001-8451-0013</orcidid><orcidid>https://orcid.org/0000-0001-9696-9227</orcidid><orcidid>https://orcid.org/0000-0002-9743-1661</orcidid><orcidid>https://orcid.org/0000-0002-8965-8495</orcidid><orcidid>https://orcid.org/0000-0002-5469-8833</orcidid><orcidid>https://orcid.org/0000-0002-4704-4532</orcidid><orcidid>https://orcid.org/0000-0001-5954-2451</orcidid><orcidid>https://orcid.org/0000-0001-6327-0487</orcidid><orcidid>https://orcid.org/0000-0003-4893-0824</orcidid><orcidid>https://orcid.org/0000-0002-4199-4019</orcidid><orcidid>https://orcid.org/0000-0002-0122-7130</orcidid><orcidid>https://orcid.org/0000-0003-3049-5182</orcidid><orcidid>https://orcid.org/0000-0002-3982-5101</orcidid><orcidid>https://orcid.org/0000-0001-8769-9157</orcidid><orcidid>https://orcid.org/0000-0003-0490-5862</orcidid><orcidid>https://orcid.org/0009-0009-5354-9949</orcidid></search><sort><creationdate>20241107</creationdate><title>Temperature guided high and very high-power short duration ablation for atrial fibrillation treatment - The peQasus multicentre study</title><author>Heeger, Christian-Hendrik ; Almorad, Alexandre ; Scherr, Daniel ; Szegedi, Nándor ; Baran, Jakub ; Duytschaever, Mattias ; Gupta, Dhiraj ; Linz, Dominik ; Lyan, Evgeny ; Leventopoulos, Georgios ; Popescu, Sorin Stefan ; Rauber, Martin ; Kollias, Georgios ; Niedzwiedz, Michał ; Sarkozy, Andrea ; Badoz, Marc ; Sohns, Christian ; Ginks, Matthew R ; Pürerfellner, Helmut ; Tilz, Roland R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c972-61264cf9a94e369a441d6936cf4e6fa6557fd6f02e235e13403f55570ed315de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heeger, Christian-Hendrik</creatorcontrib><creatorcontrib>Almorad, Alexandre</creatorcontrib><creatorcontrib>Scherr, Daniel</creatorcontrib><creatorcontrib>Szegedi, Nándor</creatorcontrib><creatorcontrib>Baran, Jakub</creatorcontrib><creatorcontrib>Duytschaever, Mattias</creatorcontrib><creatorcontrib>Gupta, Dhiraj</creatorcontrib><creatorcontrib>Linz, Dominik</creatorcontrib><creatorcontrib>Lyan, Evgeny</creatorcontrib><creatorcontrib>Leventopoulos, Georgios</creatorcontrib><creatorcontrib>Popescu, Sorin Stefan</creatorcontrib><creatorcontrib>Rauber, Martin</creatorcontrib><creatorcontrib>Kollias, Georgios</creatorcontrib><creatorcontrib>Niedzwiedz, Michał</creatorcontrib><creatorcontrib>Sarkozy, Andrea</creatorcontrib><creatorcontrib>Badoz, Marc</creatorcontrib><creatorcontrib>Sohns, Christian</creatorcontrib><creatorcontrib>Ginks, Matthew R</creatorcontrib><creatorcontrib>Pürerfellner, Helmut</creatorcontrib><creatorcontrib>Tilz, Roland R</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Europace (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heeger, Christian-Hendrik</au><au>Almorad, Alexandre</au><au>Scherr, Daniel</au><au>Szegedi, Nándor</au><au>Baran, Jakub</au><au>Duytschaever, Mattias</au><au>Gupta, Dhiraj</au><au>Linz, Dominik</au><au>Lyan, Evgeny</au><au>Leventopoulos, Georgios</au><au>Popescu, Sorin Stefan</au><au>Rauber, Martin</au><au>Kollias, Georgios</au><au>Niedzwiedz, Michał</au><au>Sarkozy, Andrea</au><au>Badoz, Marc</au><au>Sohns, Christian</au><au>Ginks, Matthew R</au><au>Pürerfellner, Helmut</au><au>Tilz, Roland R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Temperature guided high and very high-power short duration ablation for atrial fibrillation treatment - The peQasus multicentre study</atitle><jtitle>Europace (London, England)</jtitle><addtitle>Europace</addtitle><date>2024-11-07</date><risdate>2024</risdate><issn>1099-5129</issn><issn>1532-2092</issn><eissn>1532-2092</eissn><abstract>Temperature-controlled high-power short-duration (HPSD) radiofrequency catheter ablation for pulmonary vein isolation (PVI) utilizing a novel ablation catheter (QDOT Micro) with real-time assessment of catheter tip temperature aims for safer, more effective and faster procedures.
The peQasus study is a large European multicenter study set up to assess safety, acute efficacy and outcomes of temperature-controlled HPSD based PVI. The primary endpoints were safety, efficacy and 12-months freedom from atrial tachyarrhythmias. Additionally, two strategies namely very HPSD (90W for 4 seconds) only and a hybrid approach (HPSD with maximum of 50W and vHPSD) were compared.
A total of 1,023 AF patients in 15 centers from 9 European countries received PVI with the QDOT. Complete PVI was successfully achieved in all patients. In 699/1023 (68.3%) the vHPSD only approach (vHPSD group) and in 324/(31.7%) patients the hybrid approach (hybrid group) was utilized. The mean procedure duration was 98.4±37.4 min (vHPSD: 88.2±34.9min, hybrid: 117.4±32.7min, p<0.001). The first pass isolation rate of all PVs was 64% (vHPSD: 62.6%, hybrid: 67.1%, p=0.187). Severe adverse events were observed in 1.7% (vHPSD: 1.6%, hybrid: 1.9%, p=0.746). 12-month arrhythmia-recurrence free survival was 77.1% (vHPSD: 76.8%, hybrid: 77.8%, p=0.241).
In this large multicentre study temperature-controlled HPSD and vHPSD ablation via a novel ablation catheter provides safe and effective PVI with a relatively short procedure duration. Despite a shorter procedure time no differences in terms of safety and freedom from arrhythmia-recurrence were found irrespective of utilizing vHPSD or the hybrid approach.</abstract><cop>England</cop><pmid>39504572</pmid><doi>10.1093/europace/euae284</doi><orcidid>https://orcid.org/0000-0002-3490-090X</orcidid><orcidid>https://orcid.org/0000-0001-5868-5493</orcidid><orcidid>https://orcid.org/0000-0002-9014-8097</orcidid><orcidid>https://orcid.org/0000-0001-5670-745X</orcidid><orcidid>https://orcid.org/0000-0001-8451-0013</orcidid><orcidid>https://orcid.org/0000-0001-9696-9227</orcidid><orcidid>https://orcid.org/0000-0002-9743-1661</orcidid><orcidid>https://orcid.org/0000-0002-8965-8495</orcidid><orcidid>https://orcid.org/0000-0002-5469-8833</orcidid><orcidid>https://orcid.org/0000-0002-4704-4532</orcidid><orcidid>https://orcid.org/0000-0001-5954-2451</orcidid><orcidid>https://orcid.org/0000-0001-6327-0487</orcidid><orcidid>https://orcid.org/0000-0003-4893-0824</orcidid><orcidid>https://orcid.org/0000-0002-4199-4019</orcidid><orcidid>https://orcid.org/0000-0002-0122-7130</orcidid><orcidid>https://orcid.org/0000-0003-3049-5182</orcidid><orcidid>https://orcid.org/0000-0002-3982-5101</orcidid><orcidid>https://orcid.org/0000-0001-8769-9157</orcidid><orcidid>https://orcid.org/0000-0003-0490-5862</orcidid><orcidid>https://orcid.org/0009-0009-5354-9949</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1099-5129 |
| ispartof | Europace (London, England), 2024-11 |
| issn | 1099-5129 1532-2092 1532-2092 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3125484702 |
| source | Oxford Journals Open Access Collection; PubMed Central; Alma/SFX Local Collection |
| title | Temperature guided high and very high-power short duration ablation for atrial fibrillation treatment - The peQasus multicentre study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T21%3A43%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Temperature%20guided%20high%20and%20very%20high-power%20short%20duration%20ablation%20for%20atrial%20fibrillation%20treatment%20-%20The%20peQasus%20multicentre%20study&rft.jtitle=Europace%20(London,%20England)&rft.au=Heeger,%20Christian-Hendrik&rft.date=2024-11-07&rft.issn=1099-5129&rft.eissn=1532-2092&rft_id=info:doi/10.1093/europace/euae284&rft_dat=%3Cproquest_cross%3E3125484702%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3125484702&rft_id=info:pmid/39504572&rfr_iscdi=true |